Biotech RadarJobs updated

COMPANY

Dicerna Pharmaceuticals, Inc.

HQ: Cambridge, MA source · dicerna.com ↗

Clinical Phase 3

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 3 Alpha 1-Antitrypsin Deficiency Primary Hyperoxaluria Type 1 (PH1) Primary Hyperoxaluria Primary Hyperoxaluria Type 2 (PH2) Kidney Diseases Urologic Diseases Genetic Disease Primary Hyperoxaluria Type 3 (PH3) Primary Hyperoxaluria Type 2 Alcohol Use Disorder End Stage Renal Disease Chronic Hepatitis B Hepatocellular Carcinoma Multiple Myeloma Non-Hodgkins Lymphoma Pancreatic Neuroendocrine Tumors NHL DCR-PHXC nedosiran DCR-MYC DCR-STAT3 DCR-PDL1 DCR-PH1

18Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors source ↗
  2. Trial start Phase 1: A Study of DCR-STAT3 in Adults With Solid Tumors source ↗
  3. Trial start 1: Phase 1b Study of DCR-AUD in Healthy Volunteers source ↗
  4. Trial start Phase 2: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function source ↗
  5. Trial start Phase 2: An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD) source ↗
  6. Trial start Phase 1: Study of DCR-AUD in Healthy Volunteers source ↗
  7. Trial start —: Natural History of Patients With PH3 and a History of Stone Events source ↗
  8. Trial start Phase 2: Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD source ↗
  9. Trial start Phase 2: A Study of Belcesiran in Patients With AATLD source ↗
  10. Trial start Phase 1: Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients source ↗
  11. Trial start Phase 1: Study of DCR-A1AT in Healthy Adult Volunteers source ↗
  12. Trial start Phase 3: Long Term Extension Study in Patients With Primary Hyperoxaluria source ↗
  13. Trial start Phase 1: Study of Safety and Tolerability of DCR HBVS source ↗
  14. Trial start Phase 1: Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria source ↗
  15. Trial start Phase 1: A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) source ↗
  16. Trial start I: Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma source ↗
  17. Trial start I: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 18

RecordTitlePhaseStatusStartPrimary completion
NCT04042402Long Term Extension Study in Patients With Primary HyperoxaluriaPhase 3Active, not recruitingJul 9, 2019Apr 1, 2030 (estimated)
NCT06098651A Study of DCR-STAT3 in Adults With Solid TumorsPhase 1CompletedAug 14, 2023Sep 17, 2025 (actual)
NCT05001269Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionPhase 2CompletedFeb 22, 2022Feb 5, 2025 (actual)
NCT04764448A Study of Belcesiran in Patients With AATLDPhase 2TerminatedFeb 12, 2021Dec 8, 2023 (actual)
NCT05845398Phase 1b Study of DCR-AUD in Healthy Volunteers1CompletedJan 29, 2023Aug 22, 2023 (actual)
NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDPhase 2RecruitingApr 15, 2021Dec 30, 2031 (estimated)
NCT06504368Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid TumorsPhase 1RecruitingMay 29, 2024Jun 1, 2026 (estimated)
NCT05993416Treatment of Primary Hyperoxaluria Type 1 With NedosiranNot listedNo longer availableNot listedNot listed
NCT05021640Study of DCR-AUD in Healthy VolunteersPhase 1CompletedSep 21, 2021Dec 31, 2022 (actual)
NCT04542590Natural History of Patients With PH3 and a History of Stone EventsNot listedCompletedSep 9, 2021Jul 23, 2024 (actual)
NCT04174118Study of DCR-A1AT in Healthy Adult VolunteersPhase 1CompletedOct 24, 2019Jul 6, 2021 (actual)
NCT03392896Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaPhase 1CompletedDec 6, 2017Nov 19, 2019 (actual)
NCT05146882An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)Phase 2Withdrawn2021-12May 23, 2022 (actual)
NCT03772249Study of Safety and Tolerability of DCR HBVSPhase 1CompletedDec 28, 2018Jul 12, 2022 (actual)
NCT04555486Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsPhase 1CompletedSep 14, 2020Sep 7, 2021 (actual)
NCT02314052Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular CarcinomaITerminatedJan 27, 2015Oct 11, 2016 (actual)
NCT02795325A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)Phase 1TerminatedMay 13, 2016Oct 14, 2016 (actual)
NCT02110563Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaITerminated2014-04Oct 5, 2016 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback